Publicaciones en colaboración con investigadores/as de Azienda Ospedaliero-Universitaria Careggi (5)

2023

  1. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study

    Annals of Hematology, Vol. 102, Núm. 2, pp. 311-321

  2. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 15, pp. 2827-2842

  3. Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology

    JCO clinical cancer informatics, Vol. 7, pp. e2300021

2022

  1. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

    Blood Advances, Vol. 6, Núm. 17, pp. 5132-5145

2020

  1. Luspatercept in patients with lower-risk myelodysplastic syndromes

    New England Journal of Medicine, Vol. 382, Núm. 2, pp. 140-151